Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-07059-w
Abstract: This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting. We constructed a Markov model to project the lifetime direct… read more here.
Keywords: plus aspirin; cost; cardiovascular diseases; rivaroxaban plus ... See more keywords
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition.
Sign Up to like & getrecommendations! Published in 2019 at "Thrombosis research"
DOI: 10.1016/j.thromres.2019.09.033
Abstract: This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet activation. Such therapy has been… read more here.
Keywords: rivaroxaban plus; pathway inhibition; dual pathway;
Cost Effectiveness Analysis Rivaroxaban Plus Aspirin versus Aspirin alone in Treatment Cardiovascular Diseases: A Systematic Review
Sign Up to like & getrecommendations! Published in 2024 at "Medical Journal of the Islamic Republic of Iran"
DOI: 10.47176/mjiri.38.106
Abstract: Background Cardiovascular diseases (CVDs) are one of the chronic diseases and the leading cause of death worldwide. More people die from CVDs worldwide than from any other cause each year. The effects of CVDs are… read more here.
Keywords: economic evaluation; analysis; rivaroxaban plus; effectiveness ... See more keywords